How to buy Eiger Biopharmaceuticals stock (EIGR)

Eiger Biopharmaceuticals is a biotechnology business based in the US. Eiger Biopharmaceuticals shares (EIGR) are listed on the NASDAQ and all prices are listed in US Dollars. Eiger Biopharmaceuticals employs 56 staff and has a trailing 12-month revenue of around $14.7 million.

Our top picks for where to buy Eiger Biopharmaceuticals stock

Buy Eiger Biopharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Eiger Biopharmaceuticals stock price (NASDAQ: EIGR)

Use our graph to track the performance of EIGR stocks over time.

Eiger Biopharmaceuticals shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$1.10 - $8.40
50-day moving average more info button	$4.59
200-day moving average more info button	$10.27
Wall St. target price	$30.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-58.50

Is it a good time to buy Eiger Biopharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Eiger Biopharmaceuticals financials

Revenue TTM	$14.7 million
Gross profit TTM	$11.6 million
Return on assets TTM	-52.44%
Return on equity TTM	-225.93%
Profit margin	0%
Book value	$-1.08
Market Capitalization more info button	$2.6 million

TTM: trailing 12 months

Eiger Biopharmaceuticals share dividends

We're not expecting Eiger Biopharmaceuticals to pay a dividend over the next 12 months.

Have Eiger Biopharmaceuticals's shares ever split?

Eiger Biopharmaceuticals's shares were split on a 1:30 basis on 7 January 2024 . So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Eiger Biopharmaceuticals shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Eiger Biopharmaceuticals shares which in turn could have impacted Eiger Biopharmaceuticals's share price.

Eiger Biopharmaceuticals share price volatility

Over the last 12 months, Eiger Biopharmaceuticals's shares have ranged in value from as little as $1.1 up to $8.397. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eiger Biopharmaceuticals's is 1.845. This would suggest that Eiger Biopharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Eiger Biopharmaceuticals overview

Eiger BioPharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California. .

Frequently asked questions

null
What percentage of Eiger Biopharmaceuticals is owned by insiders or institutions?
Currently 11.799% of Eiger Biopharmaceuticals shares are held by insiders and 43.862% by institutions. How many people work for Eiger Biopharmaceuticals?
Latest data suggests 56 work at Eiger Biopharmaceuticals. When does the fiscal year end for Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals's fiscal year ends in December. Where is Eiger Biopharmaceuticals based?
Eiger Biopharmaceuticals's address is: 2155 Park Boulevard, Palo Alto, CA, United States, 94306 What is Eiger Biopharmaceuticals's ISIN number?
Eiger Biopharmaceuticals's international securities identification number is: US28249U1051 What is Eiger Biopharmaceuticals's CUSIP number?
Eiger Biopharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 15117E107